Catastrophic In-Stent Thrombosis with Antiphospholipid Syndrome: A case report

Clicks: 7
ID: 337470
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #389 of 408 articles by views in European Heart Journal - Case Reports

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 408 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Background In-stent thrombosis despite morphologically optimal stents remains a diagnostic challenge. Antiphospholipid syndrome is a rare cause that drives thrombosis via tissue factor– mediated coagulation—a pathway not addressed by dual antiplatelet therapy. Case summary A 51-year-old male with cardiovascular risk factors underwent primary percutaneous coronary intervention for anterior ST-elevation myocardial infarction. Ten days later he developed refractory ventricular fibrillation requiring extracorporeal cardiopulmonary resuscitation with veno-arterial extracorporeal membrane oxygenation and intra-aortic balloon pump support. Emergency angiography confirmed complete in-stent thrombosis; intravascular ultrasound excluded a mechanical cause. The intensive care course revealed a triad of red flags: unexplained in-stent thrombosis, recurrent extracorporeal circuit clotting despite stepwise heparin escalation, and arterial and venous thrombosis on full anticoagulation. This prompted antiphospholipid antibody testing, which showed persistent moderate-to-high titre anti-cardiolipin IgM—a profile within the “controversial” zone of the 2023 ACR/EULAR classification criteria. The patient was managed as APS with intensified triple therapy, later transitioning from heparin to a vitamin K antagonist, and was discharged on day 27 with no events at 3-month follow-up. Conclusion APS should be considered in unexplained in-stent thrombosis even when laboratory criteria are not strictly met. The triad of unexplained in-stent thrombosis, anticoagulationrefractory circuit clotting, and incident venous thrombosis is a clinically actionable pattern warranting empiric APS-directed management.
Reference Key
openalex_W7223905975 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors The Tien Nguyen, Phan Tiến Hóa, D. Chau, Anh Do Nguyen
Are you one of these authors? Claim your profile
Journal European Heart Journal - Case Reports
Year 2026
DOI
10.1093/ehjcr/ytag790
URL
https://doi.org/10.1093/ehjcr/ytag790
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.